Halozyme Therapeutics, Inc. (NASDAQ:HALO) was another biggest % gainer after analysts at BMO Capital Markets upgraded the stock to an Outperform rating.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) soared 12% after Five Star Equities provided equity research on the company.

Celsion Corporation (NASDAQ:CLSN) hit new 52-week high of $9.30, surpassing a $9 price target set by Dawson James set a month ago. On November 27, Dawson James began coverage on the stock with a Market Outperform rating.

Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO) extended rally on Monday as America’s flu season continues to make headlines.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was active after seekingalpha published an opinion-based article, suggesting that physicians will be more likely, at least initially, to prescribe Belviq than Qsymia. Therefore, investors were recommended to buy or add to positions in Arena.

Sequenom, Inc. (NASDAQ:SQNM) added 4.73% after Maxim Group analysts maintained their buy rating on the stock (SQNM).

Neuralstem, Inc. (NYSEAMEX:CUR) jumped 4% after FDA approved its spinal cord injury trial.

Dendreon Corporation (NASDAQ:DNDN) was among volume leaders and extended rally after Bernstein analyst lifted shares of DNDN to ‘Outperform’ while also raising the price target to $10 from $7.

DARA Biosciences Inc (NASDAQ:DARA) and Geron Corporation (NASDAQ:GERN) both gained above 3%.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) after CEO Jean-Jacques Bienaime told CNBC that thecompany has five products in clinical trials and is most excited about a treatment for Morquio syndrome, or MPS IV.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) scored fourth rally in a row after Zacks upgraded the BCRX stock from a “neutral” rating to an “outperform” rating.

Celgene Corporation (NASDAQ:CELG) hit new high after BMO Capital Markets reaffirmed its Outperform rating and lifted its price target from $101.00 to $113.00 on the stock.

Elsewhere in the industry, VIVUS, Inc. (NASDAQ:VVUS), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Biogen Idec Inc. (NASDAQ:BIIB) each edged up less than 0.5%.

Surprisingly, Novavax, Inc. (NASDAQ:NVAX), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Hemispherx BioPharma, Inc (NYSEAMEX:HEB) and Peregrine Pharmaceuticals (NASDAQ:PPHM) all ended the day without any change.

On the flip side, MannKind Corporation (NASDAQ:MNKD) declined the most among biotech stocks after The Motley Fool pointed out concerns remaining, based on its presentation at the 31st Annual J.P. Morgan Healthcare Conference and the upcoming clinical data.

Exelixis, Inc. (NASDAQ:EXEL) continued to fall after its CEO presentation at JPMorgan Healthcare Conference.

ArQule, Inc. (NASDAQ:ARQL) extended fall on failure of its lead drug candidate.

InterMune, Inc. (NASDAQ:ITMN) lost 2.25% after unveiling a plan to sell debt and stock.

Despite trading near 52-week high, Santarus, Inc. (NASDAQ:SNTS) ended lower after receiving FDA approval for UCERIS.

Infosys Ltd ADR (NYSE:INFY) edged down after the company released third-quarter results.

Galena Biopharma Inc (NASDAQ:GALE), Gilead Sciences, Inc. (NASDAQ:GILD), Cell Therapeutics Inc (NASDAQ:CTIC) and Amgen, Inc. (NASDAQ:AMGN) all lost between 0 and 1.10%.